OncoMatch/Clinical Trials/NCT02172651
Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases
Is NCT02172651 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Vitamin D3 for stage, colon cancer.
Treatment: Vitamin D3 — This study seeks to learn more about the vitamin D receptor and its relationship to colon cancer. The Vitamin D receptor is found in colon cancer cells. When Vitamin D binds to the receptor in the cancer cells, it may stop cancer cells from growing abnormally and may cause cancer cell death. Vitamin D has been used in other research studies and information from those other research studies suggests that Vitamin D may help in the treatment of colon cancer. Participants will receive either high-dose vitamin D or standard-dose vitamin D. The study drug will be given 14-28 days prior to your surgery. The number of days will depend on when the surgery is scheduled.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage I, II, III
localized, with no evidence of distant metastasis (stage I, II, or III)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Exception: allowed for patients with resectable liver metastases
No prior radiation therapy or systemic treatment is allowed for patients undergoing resection of stage I, II, or III colon cancer
Cannot have received: radiation therapy
Exception: allowed for patients with resectable liver metastases
No prior radiation therapy or systemic treatment is allowed for patients undergoing resection of stage I, II, or III colon cancer
Lab requirements
Blood counts
Participants must have normal organ and marrow function as defined below
Kidney function
Serum creatinine within normal institutional limits or creatinine clearance ≥60 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal
Liver function
Total bilirubin ≤1.5× institutional upper limit of normal (ULN); AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN, or <5x ULN if clearly attributable to liver metastases
Participants must have normal organ and marrow function as defined below: * Total bilirubin ≤1.5× institutional upper limit of normal (ULN) * AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN, or <5x ULN if clearly attributable to liver metastases * Serum calcium (corrected for albumin level) ≤ 1x institutional ULN * Serum creatinine within normal institutional limits or creatinine clearance ≥60 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify